EGFR-targeted antibody-drug conjugate

DRUG CLASS:

EGFR-targeted antibody-drug conjugate

News alerts, weekly reports and conference planners

Related drugs:

EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR amplification	Glioma	EGFR amplification	Glioma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR positive	Squamous Cell Carcinoma of Head and Neck	EGFR positive	Squamous Cell Carcinoma of Head and Neck	MRG003 Sensitive: C2 – Inclusion Criteria MRG003 Sensitive : C2	MRG003 Sensitive: C2 – Inclusion Criteria MRG003 Sensitive : C2
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BL-B01D1 Sensitive: C2 – Inclusion Criteria BL-B01D1 Sensitive : C2	BL-B01D1 Sensitive: C2 – Inclusion Criteria BL-B01D1 Sensitive : C2
MUC1 expression + EGFR expression	Esophageal Squamous Cell Carcinoma	MUC1 expression + EGFR expression	Esophageal Squamous Cell Carcinoma	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2
MUC1 expression + EGFR expression	Non Small Cell Lung Cancer	MUC1 expression + EGFR expression	Non Small Cell Lung Cancer	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2
SOX2 overexpression	Triple Negative Breast Cancer	SOX2 overexpression	Triple Negative Breast Cancer	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3
CXCR4 overexpression	Triple Negative Breast Cancer	CXCR4 overexpression	Triple Negative Breast Cancer	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3
EGFR expression	Nasopharyngeal Carcinoma	EGFR expression	Nasopharyngeal Carcinoma	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR positive	Nasopharyngeal Carcinoma	EGFR positive	Nasopharyngeal Carcinoma	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR expression	Esophageal Cancer	EGFR expression	Esophageal Cancer	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D
PIK3CA H1047R	Head and Neck Cancer	PIK3CA H1047R	Head and Neck Cancer	SHR-A1307 Sensitive: D – Preclinical SHR-A1307 Sensitive : D	SHR-A1307 Sensitive: D – Preclinical SHR-A1307 Sensitive : D
EGFR expression	Triple Negative Breast Cancer	EGFR expression	Triple Negative Breast Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D
EGFR expression + MET expression	Pancreatic Ductal Adenocarcinoma	EGFR expression + MET expression	Pancreatic Ductal Adenocarcinoma	DM005 Sensitive: D – Preclinical DM005 Sensitive : D	DM005 Sensitive: D – Preclinical DM005 Sensitive : D
EGFR expression + MET expression	Non Small Cell Lung Cancer	EGFR expression + MET expression	Non Small Cell Lung Cancer	DM005 Sensitive: D – Preclinical DM005 Sensitive : D	DM005 Sensitive: D – Preclinical DM005 Sensitive : D
EGFR overexpression	Solid Tumor	EGFR overexpression	Solid Tumor	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D
EGFR expression	Solid Tumor	EGFR expression	Solid Tumor	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D
TROP2 expression + EGFR expression	Pancreatic Cancer	TROP2 expression + EGFR expression	Pancreatic Cancer	DM001 Sensitive: D – Preclinical DM001 Sensitive : D	DM001 Sensitive: D – Preclinical DM001 Sensitive : D
TROP2 expression + EGFR expression	Lung Cancer	TROP2 expression + EGFR expression	Lung Cancer	DM001 Sensitive: D – Preclinical DM001 Sensitive : D	DM001 Sensitive: D – Preclinical DM001 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Breast Cancer	EGFR overexpression	Breast Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression + KRAS 13D	Triple Negative Breast Cancer	EGFR overexpression + KRAS 13D	Triple Negative Breast Cancer	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D
EGFR overexpression + BRAF V600E	Colorectal Cancer	EGFR overexpression + BRAF V600E	Colorectal Cancer	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D
EGFR overexpression + BRAF mutation	Colorectal Cancer	EGFR overexpression + BRAF mutation	Colorectal Cancer	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D

EGFR-targeted antibody-drug conjugate

EGFR-targeted antibody-drug conjugate

Associations(51)

Associations
(51)